Please login to the form below

Not currently logged in
Email:
Password:

Extra support for thalidomide survivors

A new compensation package for those affected by thalidomide has been unveiled by health minister, Mike O'Brien

A new compensation package for those affected by pregnancy drug, thalidomide has been unveiled by health minister, Mike O'Brien.

The drug was used between 1958 and 1961 to help control symptoms of morning sickness in expectant mothers. It was later withdrawn in 1961 after babies were born with severe physical disabilities.

Along with news of the compensation, O'Brien also offered an official apology, saying: "The Government wishes to express its deep sympathy for the injury and suffering endured by all those affected."

The scheme itself will be operated by the Thalidomide Trust, who offer support and assistance to the 466 current survivors of thalidomide.

They will be in control of a "£20m, three-year pilot scheme to meet health needs of thalidomide survivors in a more personalised way," according to O'Brien, with funding coming from existing departmental central contingency budgets.

With survivors now approaching 50, O'Brien also reported back on the National Advisory Council to the Thalidomide Trust's concerns about "the continuing and increasing health needs of Thalidomiders as they approach older age."

He said: "This additional funding will help to meet their complex and highly specialised needs, and to reduce further degeneration in their health."

14th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics